Asset Details
Do you wish to reserve the book?
Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes
Do you wish to request the book?
Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes
2025
Overview
This study aimed to assess the efficacy of ezetimibe in combination with metformin versus metformin alone in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes mellitus. Patients were randomly divided into two groups: one receiving ezetimibe and metformin (Met + EZY) and the other receiving metformin alone (Met group) for six months. Parameters were measured at baseline (T1), after three months (T2), and after six months (T3). The findings indicated that insulin levels and HOMA-IR exhibited a significant decrease from T1 to T2 in the Met + EZY group (
p
< 0.05). Malondialdehyde (MDA) and triglycerides levels also demonstrated significant decreases from T1 to T2 in the Met + EZY group (
p
< 0.05). The expression of peroxisome proliferator-activated receptor gamma (
PPAR-γ
) and adiponectin (
ADIPO
) showed a significant increase from T1 to T2 in the Met + EZY group (
p
< 0.01). Additionally,
ADIPO
expression showed a significant increase from T1 to T3 (
p
< 0.001) in both groups. When comparing the two treatment groups,
PPAR-γ
and
ADIPO
expression were significantly higher in the Met + EZY group during T2 and T3 compared to the Met group (
p
< 0.001). Combination therapy appears to be more effective than metformin treatment alone and should be used cautiously.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Aged
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - genetics
/ Diabetes Mellitus, Type 2 - metabolism
/ Ezetimibe - administration & dosage
/ Female
/ Gene Expression Regulation - drug effects
/ Glucose
/ Humanities and Social Sciences
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Kinases
/ Lipids
/ Male
/ Metformin - administration & dosage
/ Obesity
/ Peroxisome proliferator-activated receptors
/ Science
